Hints and tips:
Related Special Reports
...Marc Dunoyer, AstraZeneca’s chief financial officer, told reporters on Saturday that Soliris’s “second-generation” successor Ultomiris was about 30 per cent cheaper, while Mr Soriot noted that Sanofi-Genzyme...
...Sanofi had also provided “a long-term vision of what Genzyme would stand for within Sanofi”, protecting and reinforcing its culture, she added....
...Revenues last year were led by Sanofi’s Genzyme biotechnology unit, where growth was up 37.4 per cent, driven by its immunology and rare blood disorder franchises....
...Sanofi reported flat sales in the second quarter as a continued slowdown in its struggling diabetes division was offset by a surge in its Genzyme rare diseases unit, but the French pharmaceutical group claimed...
...Sanofi has gambled before and won; the $20bn acquisition of Genzyme in 2011 was pricey and unpopular at the time, but few are complaining now....
...After nine months of fending off advances from Sanofi, the French drugmaker, Termeer capitulated and agreed to the sale of the company for $20bn....
...Olivier Brandicourt, chief executive, said in a statement: “Sanofi Genzyme, Sanofi Pasteur and emerging markets were once again major contributors to our performance in the quarter....
...Olivier Brandicourt, chief executive officer, said in a statement: Sanofi Genzyme, Sanofi Pasteur and emerging markets were once again major contributors to our performance in the quarter....
...We will be supported by our current growth engine businesses: Sanofi Genzyme, vaccines and consumer healthcare.”...
...Overall sales were driven by the company’s specialty care Sanofi Genzyme (+17.3 per cent in 2016) and Sanofi Pasteur vaccines (+8.8 per cent) units....
...He says only one company — Genzyme, a unit of French pharmaceuticals giant Sanofi — makes the enzyme replacer that Ximena needs. Her treatment costs the Mexican state $7,700 every week....
...Once example is Genzyme, which was bought by Sanofi in 2011....
...David Meeker, executive vice-president of Sanofi Genzyme, a division of the French drugmaker Sanofi, says: “We are still finding undiagnosed patients even in the most sophisticated medical systems.”...
...Since her 2007 diagnosis, Ms Shirol has received free enzyme replacement therapy from Sanofi Genzyme, the speciality care unit of the French drugmaker, through its charitable access programme....
...David Meeker, head of the Genzyme specialty care business, a Sanofi subsidiary, said last month that rare disease assets were among the potential targets for the company as it eyes growth opportunities....
...Growth of 20 per cent in the Genzyme division, which makes treatments for rare diseases and multiple sclerosis, offset a 4.5 per cent decline in diabetes sales following the loss of patent protection on...
...We are convinced that Medivation’s employees would find a very attractive environment within our Sanofi Genzyme specialty business unit and our R&D organization, giving them the opportunity to fully develop...
...Mr Brandicourt has moved to deepen integration of Genzyme into the parent group, renaming it Sanofi Genzyme and giving it responsibility for all of Sanofi’s speciality medicines....
...They recall that the French company eventually raised its offer for Genzyme, the US biotech group it bought in 2011 for $20bn....
...Growth from vaccines and the Genzyme biotech unit helped cushion the fall in diabetes sales....
...Sales at Sanofi’s Genzyme biotech unit, which specialises in therapies for rare diseases and accounts for about 10 per cent of group revenue, rose 32.7 per cent during the quarter....
...Much of Sanofi’s most exciting science is carried out by Genzyme, the Boston-based biotech unit acquired for €20bn in 2011....
...Lower sales in the diabetes unit were more than offset by strong growth at the company’s Genzyme biotech unit and the animal health division....
...Total sales were €8.8bn, up 12.3 per cent, or 2.4 per cent excluding currency benefits, with Sanofi’s Genzyme biotech unit, animal health and emerging markets driving growth....
...Promising products are also emerging from Genzyme, the Massachusetts-based biotech company acquired for €20bn in 2011....
International Edition